These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Why does the Omicron sub-variant spread faster than the original? Callaway E Nature; 2022 Feb; 602(7898):556-557. PubMed ID: 35177843 [No Abstract] [Full Text] [Related]
5. Where did Omicron come from? Three key theories. Mallapaty S Nature; 2022 Feb; 602(7895):26-28. PubMed ID: 35091701 [No Abstract] [Full Text] [Related]
6. Symptomatic reinfection of SARS-CoV-2 with spike protein variant N440K associated with immune escape. Rani PR; Imran M; Lakshmi JV; Jolly B; Jain A; Surekha A; Senthivel V; Chandrasekhar P; Divakar MK; Srinivasulu D; Bhoyar RC; Vanaja PR; Scaria V; Sivasubbu S J Med Virol; 2021 Jul; 93(7):4163-4165. PubMed ID: 33818797 [No Abstract] [Full Text] [Related]
10. SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma. Andreano E; Piccini G; Licastro D; Casalino L; Johnson NV; Paciello I; Dal Monego S; Pantano E; Manganaro N; Manenti A; Manna R; Casa E; Hyseni I; Benincasa L; Montomoli E; Amaro RE; McLellan JS; Rappuoli R Proc Natl Acad Sci U S A; 2021 Sep; 118(36):. PubMed ID: 34417349 [TBL] [Abstract][Full Text] [Related]
11. Is preexisting immunity to seasonal coronaviruses limited to cross-reactivity with SARS-CoV-2? A seroprevalence cross-sectional study in north-eastern France. Zedan HT; Nasrallah GK EBioMedicine; 2021 Sep; 71():103580. PubMed ID: 34525435 [No Abstract] [Full Text] [Related]
13. Fc effector cross-reactivity: A hidden arsenal against SARS-CoV-2's evasive maneuvering. Grunst MW; Uchil PD Cell Rep Med; 2022 Feb; 3(2):100540. PubMed ID: 35233551 [TBL] [Abstract][Full Text] [Related]
14. Mutational Hotspot in the SARS-CoV-2 Spike Protein N-Terminal Domain Conferring Immune Escape Potential. Kubik S; Arrigo N; Bonet J; Xu Z Viruses; 2021 Oct; 13(11):. PubMed ID: 34834921 [TBL] [Abstract][Full Text] [Related]
15. The challenge of emerging SARS-CoV-2 mutants to vaccine development. Li R; Liu J; Zhang H J Genet Genomics; 2021 Feb; 48(2):102-106. PubMed ID: 33994322 [No Abstract] [Full Text] [Related]
16. Variant-proof vaccines - invest now for the next pandemic. Burton DR; Topol EJ Nature; 2021 Feb; 590(7846):386-388. PubMed ID: 33558746 [No Abstract] [Full Text] [Related]
17. Within-host evolution of SARS-CoV-2 in an immunosuppressed COVID-19 patient as a source of immune escape variants. Weigang S; Fuchs J; Zimmer G; Schnepf D; Kern L; Beer J; Luxenburger H; Ankerhold J; Falcone V; Kemming J; Hofmann M; Thimme R; Neumann-Haefelin C; Ulferts S; Grosse R; Hornuss D; Tanriver Y; Rieg S; Wagner D; Huzly D; Schwemmle M; Panning M; Kochs G Nat Commun; 2021 Nov; 12(1):6405. PubMed ID: 34737266 [TBL] [Abstract][Full Text] [Related]
18. Increased immune escape of the new SARS-CoV-2 variant of concern Omicron. Hu J; Peng P; Cao X; Wu K; Chen J; Wang K; Tang N; Huang AL Cell Mol Immunol; 2022 Feb; 19(2):293-295. PubMed ID: 35017716 [No Abstract] [Full Text] [Related]
19. Emerging mutation patterns in SARS-CoV-2 variants. Ostrov DA; Knox GW Biochem Biophys Res Commun; 2022 Jan; 586():87-92. PubMed ID: 34837837 [TBL] [Abstract][Full Text] [Related]
20. Systematic profiling of SARS-CoV-2-specific IgG epitopes at amino acid resolution. Qi H; Ma ML; Jiang HW; Ling JY; Chen LY; Zhang HN; Lai DY; Li Y; Guo ZW; Hu CS; Guo SJ; Meng QF; Ren Y; Yang X; Wang W; Zhou J; Zhao XD; Li H; Tao SC Cell Mol Immunol; 2021 Apr; 18(4):1067-1069. PubMed ID: 33664486 [No Abstract] [Full Text] [Related] [Next] [New Search]